Switching to Tenofovir Alafenamide for Chronic Hepatitis B Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the satisfaction and adherence of chronic hepatitis B patients who switch from entecavir therapy to tenofovir alafenamide (TAF). TAF is known for its convenience, requiring no dietary restrictions and less frequent dosage adjustments compared to entecavir. The study will assess improvements in patient satisfaction and adherence, as well as the efficacy of TAF therapy through changes in novel biomarkers like HBV core-related antigen. The goal is to determine if switching to TAF can enhance treatment outcomes for patients dissatisfied with their current therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. At least 20 years of age
2. Detectable serum HBsAg
3. Chronic HBV infection under ETV therapy
4. ETV users who are unsatisfied with the efficacy and/or feel inconvenient of ETV therapy
5. No contraindications for TAF switch therapy
6. HBV antiviral period expectancy for at least 1 year

Exclusion Criteria:

1. End stage renal disease (estimated glomerular filtration rate \[eGRF\]\< 15 mL/min/1.73m2) without dialysis
2. Co-infected with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus
3. Any active malignancies
4. Under immunosuppressants
5. Known allergy to tenofovir-contained regimens

Where it's running

• Taichung Veterans General Hospital
  Taichung, Taiwan, Taiwan Recruiting

Study contacts

• Principal investigator: Teng-Yu Lee, MD, PhD — Taichung Veterans General Hospital
• Study coordinator: Teng-Yu Lee, MD, PhD
• Email: tylee@vghtc.gov.tw
• Phone: +886423592525

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for patients undergoing coronary intervention with orbital atherectomy

  This study is collecting information on patients with hard-to-treat heart blockages who are getting a specific procedure called orbital atherectomy to see how safe and effective it is.

  Recruiting at 2 sites Miedziowe Centrum Zdrowia SA · Legnica, Lower Silesian Voivodeship and 1 other locations · NCT06451146

• Registry for patients with refractory angina undergoing Coronary Sinus Reducer implantation

  This study is testing if a new device called the Coronary Sinus Reducer can help people with severe chest pain who haven't found relief from other treatments.

  Recruiting at 2 sites Miedziowe Centrum Zdrowia SA · Lubin, Lower Silesian Voivodeship and 1 other locations · NCT06288165

• Evaluating bifurcation coronary interventions using two techniques

  This study looks at how well two different stenting techniques work for patients with heart artery blockages to see which one is safer and more effective.

  Recruiting at 2 sites Miedziowe Centrum Zdrowia SA · Legnica, Lower Silesian Voivodeship and 1 other locations · NCT06284057

• Registry of patients undergoing coronary interventions with shockwave therapy

  This study is collecting information on patients with hard blockages in their heart arteries who are getting a new shockwave treatment to see how safe and effective it is.

  Recruiting at 2 sites Miedziowe Centrum Zdrowia SA · Legnica, Lower Silesian Voivodeship and 1 other locations · NCT05916898

• Comparing two treatments for femoropopliteal artery disease

  This study tests whether a special balloon treatment or a stent works better for people with blocked arteries in their legs.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT05517291

• Empagliflozin with or without metformin for safety and tolerability in adults with Type 2 diabetes

  This project will try empagliflozin, with or without metformin, in adults with Type 2 diabetes to see if it is safe and well tolerated in routine clinical care at participating centers.

  Recruiting at 2 sites Phase 4 Getz Pharma · Kabul, Afghanistan and 5 other locations · NCT05164263

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.